ArticleMMWR. Morbidity and mortality weekly report2024
Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States.
Article in MMWR. Morbidity and mortality weekly report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association between vaccination and myasthenia gravis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Vaccination and rheumatoid arthritis: an updated systematic review and meta-analysis of data from 25,949,597 participants.BMC public health · 2025Pooled it
- Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines.JCI insight · 2025Trial
- Influenza vaccine awareness and uptake patterns among women of reproductive age in Pudong New Area: A community-based cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
- Adaptive multi-model ensembles for improved epidemic projections and decision support.medRxiv : the preprint server for health sciences · 2026Article
- Genomic Evolution of Influenza A Virus During the 2024-2025 Season, the Johns Hopkins Health System: Antigenic Drift Reduces Serum Neutralization.The Journal of infectious diseases · 2026Article
- Quillaja saponaria fraction QS-18 as an adjuvant for liposomal seasonal influenza vaccines.NPJ vaccines · 2026Article
- Effectiveness of Influenza Vaccine in Wuhan, China During the 2024-2025 Season: A Test-Negative Case-Control Study.Vaccines · 2026Article
- Influenza Vaccine Effectiveness Among Children With and Without Underlying Conditions.Pediatrics · 2026Article
- Delineation of the antibody light chain biases and kinetics following primary and secondary influenza virus infections of ferrets.ImmunoHorizons · 2026Article
- Influenza virus infection during pregnancy: a review of risk factors, pathogenic mechanisms, and prevention strategies.Frontiers in immunology · 2026Review
- Impact of demographic, clinical, and viral factors on severe influenza in young children in Fuzhou.Frontiers in public health · 2026Article
- Age-dependent immune landscapes affect influenza vaccine effectiveness and guide precision strategies.Frontiers in immunology · 2026Review
- Identification and validation of respiratory virus immunization using natural language processing.Frontiers in digital health · 2026Article
- Review
- Article
- Influenza vaccine effectiveness among primary and secondary school students in Shenzhen during the 2023/24 influenza season.Emerging microbes & infections · 2025Article
- Parents' preference for the inclusion of pediatric vaccines in the Chinese National Immunization Program: A discrete choice experiment.Human vaccines & immunotherapeutics · 2025Article
- The Epidemiology, Phylogeny, and Strain Antigenicity of an Influenza A/H3N2 Virus Outbreak Among Vaccinated US Navy Midshipmen.Influenza and other respiratory viruses · 2025Article
- Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023-2024 Season.The Journal of infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors.
Funding
Abstract
In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months. Using data from four vaccine effectiveness (VE) networks during the 2023-24 influenza season, interim influenza VE was estimated among patients aged ≥6 months with acute respiratory illness-associated medical encounters using a test-negative case-control study design. Among children and adolescents aged 6 months-17 years, VE against influenza-associated outpatient visits ranged from 59% to 67% and against influenza-associated hospitalization ranged from 52% to 61%. Among adults aged ≥18 years, VE against influenza-associated outpatient visits ranged from 33% to 49% and against hospitalization from 41% to 44%. VE against influenza A ranged from 46% to 59% for children and adolescents and from 27% to 46% for adults across settings. VE against influenza B ranged from 64% to 89% for pediatric patients in outpatient settings and from 60% to 78% for all adults across settings. These findings demonstrate that the 2023-24 seasonal influenza vaccine is effective at reducing the risk for medically attended influenza virus infection. CDC recommends that all persons aged ≥6 months who have not yet been vaccinated this season get vaccinated while influenza circulates locally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.